美国 · SEC FORM 4
Milestone Pharmaceuticals Inc.
MIST · Nasdaq · CIK 0001408443 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2022-12-05 · Bharucha David.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 19,009,468
- 上期报告
- 18,361,683
- 日均成交量
- 1,189,684
- 回补天数
- 16.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2022-12-05 | Bharucha David | 买入 (P) | Common Shares | 7,000 | USD 4.69 | USD 32,830 | SEC 申报 ↗ |
| 2022-12-01 | Bharucha David | 买入 (P) | Common Shares | 3,000 | USD 4.86 | USD 14,580 | SEC 申报 ↗ |
| 2022-10-21 | Liebert Debra K. | 买入 (P) | Common Shares | 4,000 | USD 5.26 | USD 21,040 | SEC 申报 ↗ |
| 2022-10-20 | Pasternak Richard C | 买入 (P) | Common Shares | 10,000 | USD 5.20 | USD 52,000 | SEC 申报 ↗ |
| 2022-10-20 | Liebert Debra K. | 买入 (P) | Common Shares | 10,000 | USD 5.29 | USD 52,900 | SEC 申报 ↗ |
| 2022-10-19 | Wills Robert James | 买入 (P) | Common Shares | 15,000 | USD 4.93 | USD 73,950 | SEC 申报 ↗ |
| 2022-10-19 | TOMSICEK MICHAEL JOHN | 买入 (P) | Common Shares | 15,000 | USD 5.32 | USD 79,800 | SEC 申报 ↗ |
| 2022-09-07 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Shares, no par value ("Common Shares") | 1,557,346 | USD 8.71 | USD 13,564,484 | SEC 申报 ↗ |
| 2022-05-31 | TRUEX PAUL F | 买入 (P) | Common Shares | 5,000 | USD 5.60 | USD 28,000 | SEC 申报 ↗ |
| 2020-03-19 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Shares | 5,870 | USD 10.87 | USD 63,807 | SEC 申报 ↗ |
| 2020-03-18 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Shares | 2,705 | USD 10.36 | USD 28,024 | SEC 申报 ↗ |
| 2020-03-02 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Shares | 78,263 | USD 18.95 | USD 1,483,084 | SEC 申报 ↗ |
| 2020-01-13 | RTW INVESTMENTS, LP; WONG RODERICK | 买入 (P) | Common Shares | 270,000 | USD 16.25 | USD 4,387,500 | SEC 申报 ↗ |
Form 4 申报证据
24 transaction lines in the latest 365-day window; 56 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-16 | Oliveto Joseph | 卖出 (S) | Common Shares | 36,500 | USD 2.26 | USD 82,490 | SEC 申报 ↗ |
| 2026-01-26 | Oliveto Joseph | 卖出 (S) | Common Shares | 34,523 | USD 1.93 | USD 66,629 | SEC 申报 ↗ |
| 2026-01-26 | Oliveto Joseph | 期权行权/转换 (M) | Common Shares | 66,600 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (24 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-16 | Oliveto Joseph | 卖出 (S) | Common Shares | 36,500 | USD 2.26 | USD 82,490 | SEC 申报 ↗ |
| 2026-01-26 | Oliveto Joseph | 卖出 (S) | Common Shares | 34,523 | USD 1.93 | USD 66,629 | SEC 申报 ↗ |
| 2026-01-26 | Oliveto Joseph | 期权行权/转换 (M) | Common Shares | 66,600 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-26 | Nelson Jeffrey Edward | 卖出 (S) | Common Shares | 12,245 | USD 1.93 | USD 23,633 | SEC 申报 ↗ |
| 2026-01-26 | Nelson Jeffrey Edward | 期权行权/转换 (M) | Common Shares | 20,100 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-26 | Muller Lorenz | 卖出 (S) | Common Shares | 11,180 | USD 1.93 | USD 21,577 | SEC 申报 ↗ |
| 2026-01-26 | Muller Lorenz | 期权行权/转换 (M) | Common Shares | 20,100 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-26 | Hasija Amit | 卖出 (S) | Common Shares | 12,245 | USD 1.93 | USD 23,633 | SEC 申报 ↗ |
| 2026-01-26 | Hasija Amit | 期权行权/转换 (M) | Common Shares | 20,100 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-26 | Bharucha David | 卖出 (S) | Common Shares | 12,245 | USD 1.93 | USD 23,633 | SEC 申报 ↗ |
| 2026-01-26 | Bharucha David | 期权行权/转换 (M) | Common Shares | 20,100 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-08 | Oliveto Joseph | 卖出 (S) | Common Shares | 43,000 | USD 2.25 | USD 96,750 | SEC 申报 ↗ |
| 2026-01-07 | Oliveto Joseph | 卖出 (S) | Common Shares | 500 | USD 2.25 | USD 1,125 | SEC 申报 ↗ |
| 2025-12-15 | Oliveto Joseph | 卖出 (S) | Common Shares | 133,054 | USD 2.32 | USD 308,685 | SEC 申报 ↗ |
| 2025-12-15 | Nelson Jeffrey Edward | 卖出 (S) | Common Shares | 58,007 | USD 2.32 | USD 134,576 | SEC 申报 ↗ |
| 2025-12-15 | Muller Lorenz | 卖出 (S) | Common Shares | 53,566 | USD 2.32 | USD 124,273 | SEC 申报 ↗ |
| 2025-12-15 | Hasija Amit | 卖出 (S) | Common Shares | 58,007 | USD 2.32 | USD 134,576 | SEC 申报 ↗ |
| 2025-12-15 | Bharucha David | 卖出 (S) | Common Shares | 58,007 | USD 2.32 | USD 134,576 | SEC 申报 ↗ |
| 2025-12-12 | Oliveto Joseph | 奖励/授予 (A) | Common Shares | 280,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-12 | Nelson Jeffrey Edward | 奖励/授予 (A) | Common Shares | 100,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-12 | Muller Lorenz | 奖励/授予 (A) | Common Shares | 100,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-12 | Hasija Amit | 奖励/授予 (A) | Common Shares | 100,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-12 | Bharucha David | 奖励/授予 (A) | Common Shares | 100,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Muller Lorenz | 赠与 (G) | Common Shares | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MIST |
| CIK | 0001408443 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 56 transaction lines from 2020-01-13 to 2026-04-16 13 P purchase lines · 16 S sale lines · 27 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.